QT Imaging Holdings, Inc. (QTI) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. QT Imaging Holdings, Inc. is a medical device company developing and commercializing the Breast Acoustic CT Scanner, a low-frequency sound wave imaging system. The company is classified as a smaller reporting company and an emerging growth company. Effective January 28, 2026, the company's common stock was uplisted to the Nasdaq Capital Market under the ticker symbol "QTI."
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $6.53 million | $2.80 million |
| Gross Profit | $2.67 million | $1.81 million |
| Gross Margin | 40.9% | 64.8% |
| Net Loss | $(3.41) million | $(11.14) million |
| Diluted EPS | $(0.25) | $(1.21) |
| Cash and Equivalents (End of Period) | $6.90 million | $3.01 million |
| Operating Cash Flow | $(3.65) million | $(3.54) million |
| Total Debt (Principal) | $10.10 million (Lynrock Lake) | $10.10 million (Lynrock Lake) |
| Related Party Notes | $3.90 million | $3.90 million |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 133% year-over-year, driven by the sale of 13 Breast Acoustic CT Scanners in Q1 2026 compared to 6 in Q1 2025.
- Margin Compression: Gross margin decreased to 40.9% from 64.8% due to higher cost of revenue associated with increased unit sales and specific inventory adjustments.
- Reduced Net Loss: Net loss improved significantly to $3.41 million from $11.14 million. The prior year loss included $8.75 million in non-recurring "Other expense, net" related to debt extinguishment and issuance costs.
- Operating Expenses: Total operating expenses rose 76% to $5.02 million, primarily due to increased headcount and professional service costs in R&D and SG&A.
- Liquidity: Cash balances decreased by $3.51 million during the quarter due to operating cash burn, partially offset by financing activities.
Outlook, Risks, and Management Commentary
- Capital Resources: Management believes current cash, the extended Lynrock Lake Term Loan (maturity extended to March 2029), and expected revenue from distribution agreements are sufficient to fund operations for at least the next 12 months.
- Debt Restructuring: On May 12, 2026 (subsequent event), the company amended its Lynrock Lake Credit Agreement to extend the maturity date to March 31, 2029, and increase the interest rate from 10% to 12% per annum.
- Distribution Agreements: The company has secured Minimum Order Quantities (MOQs) representing over $100 million in potential revenue through 2028 with partners in the U.S., Saudi Arabia, and the UAE.
- Geopolitical Risk: The filing highlights significant risk regarding military conflicts in the Middle East (specifically U.S./Israeli operations against Iran). The company states it is currently unable to ship scanners to distributors in Saudi Arabia and the UAE due to these conflicts and the closure of the Strait of Hormuz, which could materially impact revenue.
- Earnout Liability: A liability of $2.16 million remains for potential merger earnout shares, contingent on revenue milestones or stock price performance by September 30, 2026.
Investor Verification Checklist
- Geopolitical Impact: Verify the current status of shipping lanes in the Middle East and the company's ability to fulfill the Gulf Medical and Al Naghi distribution agreements.
- Debt Covenants: Review the specific financial covenants in the Lynrock Lake Credit Agreement, noting the recent interest rate increase and mandatory prepayment triggers based on accounts receivable collections.
- Customer Concentration: Confirm that "Customer A" continues to represent approximately 98% of revenue and 96% of accounts receivable.
- Warrant Liability: Monitor the fair value of the warrant liability ($276k) and the potential dilution from the Lynrock Lake Warrant (24.4 million shares exercisable at $1.0002).
- Regulatory Approvals: Track the status of regulatory approvals required to unlock the full revenue potential of the international distribution agreements (SFDA in Saudi Arabia, EDE in UAE).